Johnson & Johnson's ($JNJ) Janssen Biotech unit has made a big deal with the small biotech Pharmacyclics. Janssen will pay $150 million up front--and $975 million total, if milestones are met--for a midstage blood-cancer treatment. Report
| Wednesday, June 3rd | 11am ET / 8am PT | Presented by: Capsugel
This webinar will explore capsules' utility in a range of applications, including bioavailability enhancement, modified release, pediatric solutions, & fixed dose combinations. Learn more about how capsules enable rapid advancement of products built on QbD principles and supported by PAT. Register today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!